Search results
Showing 46 to 60 of 109 results for ovarian cancer
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
Discontinued Reference number: GID-TA10590
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Minimally invasive radical hysterectomy for early stage cervical cancer (HTG565)
Evidence-based recommendations on minimally invasive radical hysterectomy for early stage cervical cancer. This involves removing the uterus, cervix, upper vagina and some lymph nodes.
View recommendations for HTG565Show all sections
Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]
In development Reference number: GID-TA10404 Expected publication date: TBC
In development Reference number: GID-TA10483 Expected publication date: TBC
mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated with BRCA1...
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.
Discontinued Reference number: GID-TAG444
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
NG23/5 Question Premature ovarian insufficiency:- What are the main clinical manifestations of premature ovarian...
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.
Discontinued Reference number: GID-TA10168